CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

BACKGROUND: Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we invest...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Regan, Meredith M., Leyland-Jones, Brian, Bouzyk, Mark, Pagani, Olivia, Tang, Weining, Kammler, Roswitha, Dell’Orto, Patrizia, Biasi, Maria Olivia, Thürlimann, Beat, Lyng, Maria B., Ditzel, Henrik J., Neven, Patrick, Debled, Marc, Maibach, Rudolf, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Rae, James M., Viale, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2012
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3309132/
https://ncbi.nlm.nih.gov/pubmed/22395644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djs125
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares